Serial testing in women with prior stage II or III breast cancer who are clinically free of disease
Predicting early recurrence of disease in women with treated carcinoma of the breast
Indicating that additional tests or procedures should be performed to confirm recurrence of breast cancer
This test is not useful for screening women for carcinoma of the breast.
Chemiluminometric Immunoassay
Biomira Truquant BR
Breast Cancer Tumor Markers
Breast Carcinoma
Cancer Antigen 27.29 (CA 27.29)
MAM 6
Milk Mucin
CA2729
Serum
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions:
1. Centrifuge and aliquot serum into a plastic vial within 2 hours of collection. Specimens that have not been aliquoted will be canceled.
2. Send refrigerated.
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-General Request (T239)
-Oncology Test Request (T729)
0.25 mL
Gross hemolysis | Reject |
Gross lipemia | OK |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 7 days | |
Frozen | 90 days | ||
Ambient | 4 days |
Serial testing in women with prior stage II or III breast cancer who are clinically free of disease
Predicting early recurrence of disease in women with treated carcinoma of the breast
Indicating that additional tests or procedures should be performed to confirm recurrence of breast cancer
This test is not useful for screening women for carcinoma of the breast.
Carcinoma of the breast is the most prevalent form of cancer in women. These tumors often produce mucinous antigens, which are large-molecular-weight glycoproteins with O-linked oligosaccharide chains.
Monoclonal antibodies directed against these antigens have been developed, and several immunoassays are available to quantitate the levels of tumor-associated mucinous antigens in serum. The antibodies recognize epitopes of a breast cancer-associated antigen encoded by the human mucin 1 (MUC-1) gene, which is known by several names including MAM6, milk mucin antigen, cancer antigen (CA) 27.29, and CA 15-3.
While CA 27.29 is expressed at the apical surface of normal epithelial cells, it is present throughout malignant epithelial cells of the breast, lung, ovary, pancreas, and other sites. The cancer-associated form of the antigen is less extensively glycosylated than the normal form and more specific for tumor cells.
Males
> or =18 years: < or =38.0 U/mL (use not defined)
Females
> or =18 years: < or =38.0 U/mL
Reference values have not been established for patients who are younger than 18 years of age.
Serum markers are not specific for malignancy, and values may vary by method.
Increased levels of cancer-associated antigen (CA 27.29) (>38 U/mL) may indicate recurrent disease in a woman with treated breast carcinoma.
Currently, this test provides results for female patients only.
The use of cancer-associated antigen (CA 27.29) has not been demonstrated to provide clinical benefit to these patients, which has led some Mayo Clinic researchers to conclude there is insufficient justification for routine clinical use of this new marker.
Some patients who have been exposed to mouse antigens, either in the environment or as part of treatment or imaging procedure, may have circulating antimouse antibodies present. These antibodies may interfere with the assay reagents to produce unreliable CA 27.29 results.
1. Bon GG, von Mensdorff-Pouilly S, Kenemans P, van Kamp GJ, Verstraeten RA, Hilgers J: Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin Chem. 1997 Apr;43(4):585-593
2. Chan DW, Beveridge RA, Muss H: Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol. 1997 Jun;15(6):2322-2328
3. Lin DC, Genzen JR: Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. Breast Cancer Res Treat. 2018 Jan;167(1):269-276
Cancer antigen (CA) 27.29 is measured using an automated, competitive, chemiluminescent immunoassay. The signal (Lite) reagent is a monoclonal antibody specific for CA 27.29, which is labeled with acridinium ester. Purified CA 27.29 antigen attached to paramagnetic particles (solid phase) competes with the antigen in the specimen for binding to the monoclonal antibody. An inverse relationship exists between the amount of CA 27.29 in the patient specimen and the amount of relative light units detected by the system.(Package insert: Advia Centaur XPT CA 27.29. Siemens Assay Systems; 11206409_EN Rev. U, 03/2020)
Monday through Friday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
86300
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
C2729 | Breast Carcinoma Assoc Ag(CA 27.29) | 17842-6 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
C2729 | Breast Carcinoma Assoc Ag(CA 27.29) | 17842-6 |
Change Type | Effective Date |
---|---|
Test Changes - Specimen Information | 2022-08-05 |